Speakers
Ercem Atillasoy
Chief Regulatory & Safety Officer
AlloVir
Day One
Wednesday April 21
12:30 pm | Q&A/Discussion
11:40 am | Expedited Regulatory Pathways for Development & Licensure of Novel Anti-Infectives
Martin Everett
Chief Scientific Officer
AntaBio
Day One
Wednesday April 21
4:50 pm | Q&A/Discussion
4:00 pm | Pseudomonas Elastase (LasB) as a Therapeutic Target
Glenn Dale
Chief Development Officer
BioVersys
Day Two
Thursday April 22
12:30 pm | Q&A/Discussion
11:15 am | BV100 – a Novel Therapy for Antibiotic-Resistant Acinetobacter Infections
Kevin Outterson
Executive Director & Professor of Law
CARB-X & Boston University
Day One
Wednesday April 21
10:15 am | Q&A/Discussion
9:25 am | Surviving FDA Approval of your Antibiotic
Cara Cassino
Executive Vice President of R&D & Chief Medical Officer
ContraFect
Day Two
Thursday April 22
9:50 am | Q&A/Discussion
9:00 am | Direct Lytic Agents (DLA): New Medical Modalities for Life- Threatening, Drug-Resistant Infections
David Altarac
Chief Medical Officer
Entasis Therapeutics
Day Two
Thursday April 22
12:30 pm | Q&A/Discussion
12:05 pm | Targeted Therapy for Rare Pathogens: Challenges & Opportunities
Marc Navre
Chief Executive Officer & Chief Scientific Officer
Facile Therapeutics
Day One
Wednesday April 21
4:50 pm | Q&A/Discussion
4:25 pm | A De-Risked Small Molecule Anti-Toxin for the Treatment of C.difficile Infections
Dave Ousterout
Chief Scientific Officer
Locus Biosciences
Day One
Wednesday April 21
2:40 pm | Q&A/Discussion
1:50 pm | Clinical Experience with crPhage in Urinary Tract Infections
Silas Holland
Head of External Affairs (Interim) & Director of Global Public Policy
The AMR Action Fund & Merck
Day One
Wednesday April 21
10:15 am | Q&A/Discussion
9:00 am | AMR Action Fund: Strengthening & Accelerating Antibiotic Development
Mike Gordeev
Chief Scientific Officer
MicuRx Pharmaceuticals
Day Two
Thursday April 22
2:50 pm | Q&A/Discussion
2:25 pm | Novel Investigational Polymyxin MRX-8 with an Improved Safety & Efficacy against Key Gram-Negative Infections
John George
Co-Founder & Chief Scientific Officer
Oppilotech
Ed Siegwart
Director of Microbiology
Oppilotech
Jonathan Steckbeck
Founder, President & Chief Executive Officer
Peptilogics
Day One
Wednesday April 21
12:30 pm | Q&A/Discussion
12:05 pm | Differentiated Approach to Harnessing Novel Biologics & Overcome AMR
Jeanette Mucha
Chief Executive Officer & Co- Founder
SciBac
Day One
Wednesday April 21
2:40 pm | Q&A/Discussion
2:15 pm | Fighting Fire with Fire: Live Biotherapeutics for Pulmonary Infections
Angela Talley
Vice President of Clinical Development
Spero Therapeutics
Day Two
Thursday April 22
12:30 pm | Q&A/Discussion
11:40 am | Ensuring Anti-Infective Economic Sustainability by Targeting the Unmet Medical Need
David Powell
Chief Scientific Officer
Summit Therapeutics
Day Two
Thursday April 22
9:50 am | Q&A/Discussion
9:25 am | Building a Pipeline of New Mechanism Antibiotics that Drives Commercial Sustainability through Clinical Superiority
Nrusingh Mohapatra
Chief Scientific Officer
Techulon
Day Two
Thursday April 22
2:50 pm | Q&A/Discussion
2:00 pm | Obstacles for Discovery & Development of Narrow Spectrum Antimicrobials
Joseph DiMasi
Director of Economic Analysis
Tufts CSDD
Day One
Wednesday April 21
10:15 am | Q&A/Discussion
9:50 am | Trends in the Development & Approval of New Anti-infectives: Cycle Times, Success Rates & Expedited Regulatory Pathways
Silvia Caballero
Associate Director of Infectious Diseases
Vedanta Biosciences
Bernat Olle
Chief Executive Officer
Vedanta Biosciences
James Crowe
Director
Vanderbilt Vaccine Center
Mohammad Seyedsayamdost
Associate Professor of Chemistry & Molecular Biology
Princeton University
Peter Beyer
Senior Advisor and Team Lead
World Health Organization - WHO
Day One
Wednesday April 21
8:30 am | Keynote Presentation: A Review of the Antibacterial Development Pipeline
